China Blood Product Industry Report, 2014-2017

Posted by David Lee at 01:11 on Friday 11 July 2014
ResearchMoz.us include new market research report " China Blood Product Industry Report, 2014-2017: Industry Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports.

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods).


However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis.

Because of robust demand from China blood products market, the total lot release volume of imported human albumin reached 14.39 million bottles (about 10g/bottle) in 2013, a year-on-year increase of 24.1%, accounting for 53.4% (45.3% in 2012) of the total lot release volume of human albumin during the same period. Assuming absolute superiority, Behring, Baxter, Grifols and Octapharma still held the ground as the top four exporters of human albumin to China.

Despite a slight year-on-year decline in output and sales volume, major Chinese blood products companies, by and large, maintained steady revenue growth in 2013, thanks to rising prices of blood products (the highest retail prices of fibrinogen and blood coagulation factor VIII rose over 50% year on year). China Biologic Products, Hualan Bio, Tiantan Biological Products, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which hold combined 60% of the total plasma volume, generated total revenue of about RMB4.2 billion in 2013, up 13.5% year on year. Among them, Shanghai RAAS, due to production halt caused by flood, earned only RMB496 million, down 25.1% year on year.

Browse More related reports to Biotechnology at: http://www.researchmoz.us/biotechnology-market-reports-30.html

Attracted by national policy support and high market prosperity, qualified Chinese blood products companies are actively engaged in construction of new plasma stations, some of which are expected to collect plasma by the end of 2014. In June 2014, Wuhan Zhongyuan Ruide Biological Product Co., Ltd. (100% controlled by Humanwell Healthcare (Group) Co., Ltd.)’s plasmapheresis center in Chibi was approved to collect plasma; In May 2014, Hualan Bio’s plasma station in Hua County, Henan Province was approved to be set up; In April 2014, Hebei Da'an Pharmaceutical (90% stake controlled by Walvax Biotechnology Co., Ltd.) carried out on-site GMP compliance certification for its plasma station in Wei County; At the end of 2013, Guangdong Shuanglin Bio-pharmacy’s plasma stations in Xi County and Jiang County of Shanxi were completed.



About Us:

ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact: 
Mrs.Sheela AK
Tel:+1-518-618-1030 
Toll Free: 866-997-4948
Labels: , ,

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)